ASND
Ascendis Pharma A/S
103.10
USD
This page is just a preview of the data found in TrendSpider’s full version
Ascendis Pharma A/S stock is up 15.47% since 30 days ago. The next earnings date is Feb 15, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 44.44% of the previous 8 December’s closed higher than November. In the last 2 Unusual Options Trades, there were 1 CALL, 1 PUT. 50% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 11 Oct 14:38 | 17 Jan, 2025 | 90.00 | 20 | ||
| 06 Nov 14:53 | 15 Dec, 2023 | 85.00 | 284 |
SKYTROFA for treating patients with growth hormone deficiency (GHD) Ascendis Pharma A/S focuses on developing therapeutics for unmet medical needs. It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD. TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia.
